Replies to post #16 on Theseus Pharmaceuticals Inc (THRX)

[surf1944]

7. Theravance Inc. (THRX): Biotechnology Industry. Market cap of $1.86B. Current price at $21.99 vs. target price of $27.8 (implies a potential upside of 26.42%). Net insiders purchases over the last 6 months is 5.19M shares, which represents 9.92% of the 52.32M share float. The stock is a short squeeze candidate, with a short float at 8.61% (equivalent to 14.23 days of average volume). The stock has performed poorly over the last month, losing 13.19%.

http://seekingalpha.com/article/276281-10-undervalued-biotech-stocks-with-insider-buying?source=yahoo